A Study of Ibrutinib in Combination With Rituximab in Japanese Participants With Waldenstrom's Macroglobulinemia (WM)

  • STATUS
    Recruiting
  • End date
    Jun 1, 2023
  • participants needed
    14
  • sponsor
    Janssen Pharmaceutical K.K.
Updated on 22 November 2020
rituximab
monoclonal antibodies
measurable disease
monoclonal antibody therapy
monoclonal protein
immunoglobulin
ibrutinib

Summary

The purpose of this study is to evaluate overall response rate (ORR) by Independent Review Committee (IRC) assessment, when combined with rituximab in Japanese participants with treatment nave or relapsed/refractory Waldenstrom's Macroglobulinemia (WM).

Details
Treatment Rituximab, Ibrutinib
Clinical Study IdentifierNCT04062448
SponsorJanssen Pharmaceutical K.K.
Last Modified on22 November 2020

Adding a note
adding personal notes guide

Select a piece of text and start making personal notes.

Similar trials to consider

Loading...

Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

Study

user name

Annotated by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No made yet